CDRH Examining CryoLife Heart Valve Risks Following Tissue Recall
This article was originally published in The Gray Sheet
Executive Summary
CDRH is reviewing potential risks associated with CryoValve heart valves in the wake of an Aug. 14 recall order for CryoLife human tissue products
You may also be interested in...
CryoLife, FDA Extend Interim Operating Agreement To March 20
CryoLife anticipates filing an investigational device exemption submission with FDA to expand the indication of BioGlue for the sealing of dura mater by late 2003
CryoLife, FDA Extend Interim Operating Agreement To March 20
CryoLife anticipates filing an investigational device exemption submission with FDA to expand the indication of BioGlue for the sealing of dura mater by late 2003
Cryolife Preparing For FDA Reinspection, Files Corrective Action Plan
Cryolife says it expects to be ready for an FDA reinspection of its Kennesaw, Georgia facility by early December. On Oct. 8, the company submitted a corrective action plan outlining proposed steps to validate its tissue processing procedures